Chugai Pharmaceutical Aktie
| 38,31EUR | -0,46EUR | -1,19% |
WKN: 857216 / ISIN: JP3519400000
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Roche Holding AG | 59,89 |
| Freefloat | 37,20 |
| Chugai Pharmaceutical Co., Ltd. | 2,00 |
| Nomura Asset NEXT FUNDS NIKKEI 225 ETF (1321) | 1,59 |
| Nomura Asset NEXT FUNDS TOPIX ETF (1306) | 1,09 |
| Vanguard Health Care Fund | 1,05 |
| Nikko Exchange Traded Index Fund 225 | 0,77 |
| Daiwa Asset iFreeETF NIKKEI 225 (Yearly Dividend Type) (1320) | 0,72 |
| Sumitomo Life Insurance Co. | 0,54 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 7 394 | 7 555 | 7 664 | 7 771 | 7 604 |
| Umsatz pro Mitarbeiter in Mio. EUR | 92,80 | 104,16 | 130,45 | 162,13 | 146,16 |
Bilanz (in Mio. JPY) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 699 680 | 834 906 | 1 063 661 | 1 336 537 | 1 366 426 |
| Summe Anlagevermögen | 359 235 | 400 592 | 475 033 | 533 221 | 566 121 |
| Summe Aktiva | 1 058 915 | 1 235 498 | 1 538 694 | 1 869 758 | 1 932 547 |
Bilanz (in Mio. JPY) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 12 752 | 11 284 | 16 040 | 14 109 | 13 455 |
| Summe Fremdkapital | 204 929 | 255 494 | 350 677 | 445 371 | 306 966 |
| Summe Eigenkapital | 853 985 | 980 003 | 1 188 017 | 1 424 387 | 1 625 580 |
| Summe Passiva | 1 058 914 | 1 235 497 | 1 538 694 | 1 869 758 | 1 932 546 |
Adresse
| Nihonbashi Mitsui Tower, 15/F, 103-8324 Tokyo | |
| Telefon | +81 (3) 3281-6611 |
| Fax | +81 (3) 3281-6607 |
| Internet | http://www.chugai-pharm.co.jp |
Management
|
Atsushi Sato
Auditor |
|
Christoph Franz
Director |
|
Hisafumi Okabe
Senior Executive Officer & Head-Research |
|
Iwaaki Taniguchi
Chief Financial Officer, Director & Executive VP |
|
James H. Sabry
Director |
|
Junichi Ebihara
Senior Executive Officer & Manager-Legal Affairs |
|
Junichi Nezu
Executive Officer, GM-Research & Development |
|
Keiji Kono
Senior Executive Officer & Head-External Affairs |
|
Mamoru Togashi
Auditor |
|
Mariko Momoi
Independent Outside Director |
|
Masayuki Oku
Independent Outside Director |
|
Minoru Watanabe
Executive Officer |
|
Motoo Ueno
Vice Chairman & Head-Audit |
|
Osamu Okuda
President, CEO & Representative Director |
|
Shinji Hidaka
Executive Officer & General Manager-Sales |
|
Shinya Unno
Head-Personnel, Legal & General Affairs |
|
Toshihiko Komori
Executive Officer |
|
William N. Anderson
Director |
|
Yasushi Ito
Senior Executive Officer |
|
Yoichiro Ichimaru
Independent Outside Director |
|
Yoko Kitagawa
Group Manager-Finance & Accounting |
|
Yoshiaki Ohhashi
Head-Quality & Regulatory Compliance Unit |
|
Yoshiyuki Yano
Executive Officer & Manager-Personnel |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
